CD123 Expression Is Associated With High-Risk Disease Characteristics in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group In this open-label, randomized phase II-III study ...

Please provide your email address to receive an email when new articles are posted on . The addition of modified FOLFIRINOX induction chemotherapy to standard care improved metastasis-free survival.

Announced extraordinary 86% overall survival at 9 months in first-line pancreatic cancer patients treated with atebimetinib + mGnP - - Raised $225 million of financing, including $25 million private ...

More than 30% of patients with pancreatic cancer are unresectable because of the local extension with a median overall survival (OS) of <1 year. Combination of fluorouracil (FU), oxaliplatin, and ...

Pelareorep combined with modified FOLFIRINOX, with or without Tecentriq, shows an acceptable safety profile in metastatic PDAC patients. All patients experienced side effects, with some severe cases, ...

Pancreatic cancer survival has finally doubled in a decade to 13 percent, a fragile but real sign that years of slow, ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Samuel J. Klempner ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Omitting bolus 5 ...

Company evaluating systemic recombinant human DNase I (DNase I) in combination with chemotherapy and immunotherapy platforms for the treatment of pancreatic carcinoma, colorectal cancer and other ...